CEP85L

Across TCGA pan-cancer cohorts, CEP85L RNA differs between tumor and matched normal tissue in 13 of 18 cancer types tested, making tumor–normal expression one of CEP85L’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where CEP85L RNA is more highly expressed in tumor relative to normal tissue. In most cancer types CEP85L is over-expressed in tumor, although a few such as THCA and BLCA show the opposite, repressed pattern.

KIRC, THCA, and BLCA are the cancer types where CEP85L tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in CEP85L RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	All	All	+0.506	<.001	11	view →
THCA	Male	III,IV	−0.849	<.001	10	view →
BLCA	Male	III,IV	−1.452	<.001	8	view →
LUSC	Female	All	−0.732	<.001	8	view →
COAD	Female	All	−0.465	<.001	8	view →
KICH	Female	All	−0.643	<.001	7	view →
UCEC	All	II,III,IV	−1.000	<.001	6	view →
BRCA	All	III,IV	−0.791	<.001	6	view →
LUAD	All	III,IV	−0.399	.011	3	view →
READ	Female	All	−0.877	.013	2	view →
PRAD	All	All	−0.244	.020	2	view →
STAD	All	IV	−0.803	.016	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 13 lineages.

CEP85L–KIRC

Open the KIRC breakdown →